Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S./EU Filings Position Bayer Compound As First Approval For CTEPH

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bayer has filed riociguat, a first-in-class oral soluble guanylate cyclase stimulator, in the U.S. and Europe for approval in both pulmonary arterial hypertension and a related condition, persistent/recurrent chronic thromboembolic pulmonary hypertension. The compound stands to become the first drug therapy approved for CTEPH.

You may also be interested in...



FDA Panel Endorses Riociguat For CTEPH Amid Worries It Will Displace Surgery

Committee unanimously recommends Bayer’s Adempas for two indications, but members say measures are needed to ensure that patients with chronic thromboembolic pulmonary hypertension are not automatically steered to the novel vasodilator when they could benefit from potentially curative surgery.

FDA Review Of Bayer’s Riociguat Suggests It’s All About The Dose

Agency will seek Cardiovascular and Renal Drugs Advisory Committee’s views on a dosing algorithm for the novel pulmonary arterial hypertension drug; FDA clinical reviewer recommends approval but with lower starting and maximum doses than those used in the pivotal trials due to risk of drug-induced hypotension.

Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns

It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel